Page last updated: 2024-12-05

quinoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Quinoline is a heterocyclic organic compound with the formula C9H7N. It is a colorless hygroscopic liquid with a pungent odor. Quinoline is a planar molecule with a bicyclic structure consisting of a benzene ring fused to a pyridine ring. Quinoline is found naturally in coal tar and is a common synthetic intermediate. It is a weak base and can be protonated to form a quinolinium cation. Quinoline is an important starting material for the synthesis of a variety of pharmaceuticals, dyes, and other fine chemicals. Quinoline derivatives have a wide range of biological activities, including antimalarial, antibacterial, antifungal, and anticancer activity. Quinoline is studied due to its diverse applications in medicine, agriculture, and industry. Quinoline derivatives have been used to treat malaria, tuberculosis, and other infections. They have also been used as pesticides and herbicides. Quinoline is a versatile and important compound with a wide range of applications.'

Cross-References

ID SourceID
PubMed CID7047
CHEMBL ID14474
CHEBI ID17362
SCHEMBL ID2774
SCHEMBL ID1193639
SCHEMBL ID3311562
SCHEMBL ID8571823
SCHEMBL ID483852
MeSH IDM0112769

Synonyms (129)

Synonym
BIDD:ER0666
bdbm50047015
chinolin
wln: t66 bnj
1-azanaphthalene
chinoline
leucol
b 500
chinoleine
1-benzazine
usaf ek-218
nsc-3396
1-benzine
nsc3396
benzopyridine
leukol
quinolin
CHEBI:17362 ,
ai3-01241
2,3-benzopyridine
ccris 547
fema no. 3470
quinoline (8ci,9ci)
AE-641/01960007
inchi=1/c9h7n/c1-2-6-9-8(4-1)5-3-7-10-9/h1-7
NCGC00091190-01
un2656
chinolin [czech]
benzo(b)pyridine
quinoline [un2656] [poison]
einecs 202-051-6
benzopyridine (van)
91-22-5
quinoline ,
C06413
benzo[b]pyridine
quinoline, >=97%
quinoline, reagent grade, 96%
quinoline, reagent grade, 98%
hsdb 121
b-500 ,
nsc 3396
NCIOPEN2_007906
Q0085
MLS002303065
smr000112309
CHEMBL14474 ,
Q0011
AKOS000119139
NCGC00091190-02
NCGC00091190-03
NCGC00091190-04
dtxsid1021798 ,
cas-91-22-5
NCGC00259029-01
NCGC00254119-01
tox21_201478
tox21_300068
dtxcid401798
BBL011390
HMS2271F08
STL146493
e66400vt9r ,
quinoline [un2656] [poison]
unii-e66400vt9r
ec 202-051-6
FT-0602839
EPITOPE ID:140096
quinoline [iarc]
quinoline [fhfi]
quinoline [mi]
quinoline [hsdb]
S6369
SCHEMBL2774
SCHEMBL1193639
quinoline-
SCHEMBL3311562
SCHEMBL8571823
SCHEMBL483852
STR01546
un 2656
J-524185
F0001-2218
quinoline > 90% grade
quinoline, analytical standard
mfcd00006736
quinoline, >=99%
quinoline, jis special grade, >=95.0%
quinoline, saj first grade, >=94.0%
EN300-19120
quinoline, for synthesis, 96.0%
quinoline 500 microg/ml in methanol
fema 3470
quinoline (d7)
Q408384
15793-87-0
mfcd31699985
SY246330
SY246332
mfcd31699986
15793-82-5
mfcd31699984
SY246281
SY246333
quinoline-5-d
mfcd31699982
quinoline-4-d
15793-85-8
15793-84-7
mfcd31699983
quinoline-3-d
quinoline-6-d
SY246331
15793-83-6
SY246329
mfcd31699987
15793-86-9
quinoline-7-d
quinoline-8-d
AMY38997
hydroquinoline
D97671
quinoline, redistilled from glass
31177-31-8
benzo (b) pyridine
quinoline (iarc)
1-benzazene
1-azanapthalene
Z104472852

Research Excerpts

Overview

Quinoline is an N-heterocyclic compound commonly found in wastewater, especially that derived from coal processing, chemical, and pharmaceutical industries. Quinoline is a hepatocarcinogen in mice and rats, a mutagen in Salmonella typhimurium, and induces unscheduled DNA synthesis in rat hepatocytes.

ExcerptReferenceRelevance
"Quinoline is an N-heterocyclic compound commonly found in wastewater, especially that derived from coal processing, chemical, and pharmaceutical industries. "( Effect of Quinoline on the Phospholipid Profile of
Bernat, P; Felczak, A; Lisowska, K; Nowak-Lange, M; Zawadzka, K, 2022
)
2.57
"Quinoline is a recalcitrant pollutant in coking wastewater which has been broadly investigated with many isolates possessing aerobic quinoline-degrading ability. "( Antibiotic-induced role interchange between rare and predominant bacteria retained the function of a bacterial community for denitrifying quinoline degradation.
Chen, G; Ji, M; Wang, T; Wu, X; Zhang, X; Zhong, S, 2020
)
2.2
"Quinoline is a privileged scaffold especially known with antimalarial and antibacterial drugs before, presently followed anticancer efficiency with a new group of protein kinase inhibitors."( New Quinoline Based Sulfonamide Derivatives: Cytotoxic and Apoptotic Activity Evaluation Against Pancreatic Cancer Cells.
Çiftçi, GA; Yurttaş, L, 2018
)
2.48
"Quinoline is a refractory organic compound in the treatment of coking wastewater. "( Quinoline-degrading strain Pseudomonas aeruginosa KDQ4 isolated from coking activated sludge is capable of the simultaneous removal of phenol in a dual substrate system.
Chai, T; Jia, R; Shi, P; Zhang, P; Zhang, Y, 2016
)
3.32
"Quinoline is a N-heterocyclic compound often found at tar oil contaminated field sites. "( Carbon and hydrogen isotope fractionation during anaerobic quinoline degradation.
Fischer, A; Hollender, J; Reineke, AK; Richnow, HH; Weber, S, 2010
)
2.05
"Quinoline is a hepatocarcinogen in mice and rats, a mutagen in Salmonella typhimurium, and induces unscheduled DNA synthesis in primary cultures of rat hepatocytes. "( On the metabolism of quinoline and isoquinoline: possible molecular basis for differences in biological activities.
Adams, EA; Hoffmann, D; La Voie, EJ; Shigematsu, A, 1983
)
2.03
"Quinoline is a hepatocarcinogen in rats and mice and a well-known mutagen in bacteria after incubation with rat liver microsomes. "( Cytochrome P450 species involved in the metabolism of quinoline.
Esumi, Y; Green, C; Ishizaki, M; McMahon, H; Ninomiya, S; Ohara, T; Reigh, G; Shimane, K; Tyson, C, 1996
)
1.99
"Quinoline is a specific and potent carcinogen to the rat and mouse liver. "( Quinoline: unscheduled DNA synthesis and mitogenesis data from the rat liver in vivo.
Ashby, J; Bandara, L; Lefevre, PA; Mohammed, R, 1989
)
3.16

Effects

Quinoline has become one of the common contaminants in groundwater and soil, discharged from the process of coal tar distillation. Quinoline has not been reported previously from an animal source.

ExcerptReferenceRelevance
"Quinoline derivatives have been reported to possess enticing pharmacological properties. "( Identification of quinoline-chalcones and heterocyclic chalcone-appended quinolines as broad-spectrum pharmacological agents.
Atukuri, D; L, V; M M, R; R, P; R, S; S, V, 2020
)
2.33
"Quinoline has become one of the common contaminants in groundwater and soil, discharged from the process of coal tar distillation and creosote wood preservation, as well as fossil fuel facilities. "( Electricity production from and biodegradation of quinoline in the microbial fuel cell.
Liu, G; Luo, H; Zhang, C; Zhang, R, 2010
)
2.06
"Quinoline has not been reported previously from an animal source."( Defensive production of quinoline by a phasmid insect (Oreophoetes peruana).
Attygalle, AB; Eisner, T; Herath, KB; Meinwald, J; Morgan, RC; Smedley, SR, 1997
)
1.33

Actions

ExcerptReferenceRelevance
"Quinoline scaffold plays an important role in anticancer drug development as their derivatives have shown excellent results through different mechanism of action such as growth inhibitors by cell cycle arrest, apoptosis, inhibition of angiogenesis, disruption of cell migration, and modulation of nuclear receptor responsiveness."( A review on anticancer potential of bioactive heterocycle quinoline.
Afzal, O; Ali, MR; Bawa, S; Haider, MR; Jaggi, M; Kumar, R; Kumar, S, 2015
)
1.38

Treatment

ExcerptReferenceRelevance
"Rats treated with quinoline, and to a lesser extent, isoquinoline (75 mg/kg, daily for 3 days) showed induction of phase II drug metabolizing enzyme activities without inducing either cytochrome P450 concentration or CYP1A-, CYP2B-, CYP2E-, and CYP3A-selective activities. "( Selective induction of phase II drug metabolizing enzyme activities by quinolines and isoquinolines.
Franklin, MR; Le, HT, 1997
)
0.86

Toxicity

An adverse effect on algae was observed only for the parent compounds quinoline and isoquinoline. In the Daphnia magna immobilization assay most hydroxylated qu inoline derivatives showed toxicity. Modified gold nanoparticles having functional quin Caroline molecules (GNPs@L) were also synthesized and their sensing properties towards different metal ions were also explored.

ExcerptReferenceRelevance
"Many nitrogen-heterocyclic compounds (NHCs) are toxic and recalcitrant contaminants that need to be degraded by advanced oxidation processes."( Toxicity change patterns and its mechanism during the degradation of nitrogen-heterocyclic compounds by O(3)/UV.
Huang, X; Wang, XM, 2007
)
0.34
" Effect concentrations expressed as soil pore-water concentrations were related to log K(ow), which indicated narcosis as the most probable mode of toxic action."( Toxicity of four nitrogen-heterocyclic polyaromatic hydrocarbons (NPAHs) to soil organisms.
Bezchlebová, J; Hofman, J; Kobetičová, K; Lána, J; Sochová, I, 2008
)
0.35
" An adverse effect on algae was observed only for the parent compounds quinoline and isoquinoline, while in the Daphnia magna immobilization assay most hydroxylated quinoline derivatives showed toxicity."( Ecotoxicity of quinoline and hydroxylated derivatives and their occurrence in groundwater of a tar-contaminated field site.
Eisentraeger, A; Hollender, J; Neuwoehner, J; Reineke, AK, 2009
)
0.94
"The aim of this study was to compare the toxic effects of selected two- and three-ringed PAHs (naphthalene, phenanthrene, and anthracene) and their N-heterocyclic analogs with one (quinoline, acridine, and phenanthridine) or two (quinoxaline, phenazine, and 1,10-phenanthroline) nitrogen atoms on the survival and reproduction of Enchytraeus crypticus in artificial soil."( Toxic effects of nine polycyclic aromatic compounds on Enchytraeus crypticus in artificial soil in relation to their properties.
Brezovský, J; Hofman, J; Kobetičová, K; Simek, Z, 2011
)
0.56
" Modified gold nanoparticles having functional quinoline molecules (GNPs@L) were also synthesized and their sensing properties towards different metal ions were also explored in solution, showing high selectively towards the toxic and heavy metal ion mercury."( A novel quinoline molecular probe and the derived functionalized gold nanoparticles: sensing properties and cytotoxicity studies in MCF-7 human breast cancer cells.
Capelo, JL; Diniz, M; García-Pardo, J; Lodeiro, C; Lorenzo, J; Núñez, C; Oliveira, E, 2014
)
1.09
" Compounds 2 and 3 were found to be more toxic than compound 1; apoptotic staining assays indicated that compound 3 causes increased cell death."( Discovery of Quinoline-Derived Trifluoromethyl Alcohols, Determination of Their in vivo Toxicity and Anticancer Activity in a Zebrafish Embryo Model.
Arambula, JF; Blocker, M; Bowe, K; Cade, HC; Graves, VB; Heimberger, J; Immaneni, S; Luke, S; McCall, R; Padgett, J; Salter, P; Shaikh, A; Sittaramane, V; Van Leuven, D; Williams, A, 2015
)
0.79

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic properties of drugs may be altered by kinetic deuterium isotope effects."( Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
Clark, AJ; Gao, H; Obach, RS; Ripp, SL; Schildknegt, K; Sharma, R; Spracklin, DK; Strelevitz, TJ; Tremaine, LM; Vaz, AD, 2012
)
0.38
" Snapshot pharmacokinetic analysis demonstrated that the antiplasmodial activity of these C-10-acetal artemisinin dimers may be due to active metabolites, which were confirmed by in silico findings."( Antimalarial and anticancer activities of artemisinin-quinoline hybrid-dimers and pharmacokinetic properties in mice.
Breytenbach, JC; Denti, P; Kolesnikova, NI; Lombard, MC; N'Da, DD; Norman, J; Tran Van Ba, C; Vial, H; Wein, S; Wiesner, L, 2012
)
0.63
" A pharmacokinetic (PK) absorption model was employed to guide the formulation development and selection."( Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic Analysis.
Crison, J; Fung, NK; Good, DJ; Haddadin, R; Hartley, R; Hussain, M; Koo, O; Mathias, N; Nikfar, F; Timmins, P; Tirucherai, G, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" To improve the bioavailability and increase the efficiency of aminosteroid E-37P, two series of analog compounds were synthesised by classic chemical synthesis, they were then characterized, and the concentration that inhibits 50% of cell proliferation (IC50) was determined on different cell lines."( Chemical synthesis, cytotoxicity, selectivity and bioavailability of 5α-androstane-3α,17β-diol derivatives.
Ayan, D; Hospital, A; Maltais, R; Poirier, D, 2014
)
0.4
" RG7834, a compound from the dihydroquinolizinone (DHQ) chemical series, is a first-in-class highly selective and orally bioavailable HBV inhibitor which can reduce both viral antigens and viral DNA with a novel mechanism of action."( Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action.
Cheng, Z; Han, X; Javanbakht, H; Jiang, M; Liang, C; Liu, Y; Luangsay, S; Lv, W; Mayweg, AV; Shen, HC; Wang, J; Wang, M; Wang, Y; Wang, Z; Weikert, R; Xie, J; Yang, S; Yu, X; Zhou, C; Zhou, X, 2018
)
0.48
" These compounds were found to be orally bioavailable and highly effective."( Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
Eswaran, S; Narayanan, S; Shivarudraiah, P; Shruthi, TG; Subramanian, S, 2019
)
0.75
" Extensive SAR and DMPK studies led to the identification of 20j, a potent and orally bioavailable MET kinase inhibitor with favorable kinase selectivity."( Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate.
Chen, T; Fang, WR; Huang, W; Li, YM; Liu, PF; Zhuo, LS, 2020
)
0.79
" Owing to limitations like drug resistance, high cost, severe side effects, and less bioavailability of previously synthesized antimicrobial agents, these drugs have become obsolete in recent years."( Recent update on antibacterial and antifungal activity of quinoline scaffolds.
Dorababu, A, 2021
)
0.87

Dosage Studied

Quinoline did, however, induce a potent mitogenic response in the rat liver between 24 and 48 hr after oral dosing of 200-500 mg/kg.

ExcerptRelevanceReference
" Quinoline did, however, induce a potent mitogenic response in the rat liver between 24 and 48 hr after oral dosing of 200-500 mg/kg."( Quinoline: unscheduled DNA synthesis and mitogenesis data from the rat liver in vivo.
Ashby, J; Bandara, L; Lefevre, PA; Mohammed, R, 1989
)
2.63
" Oral dosing (0."( Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold.
Cao, GQ; Chakrabarti, PP; Falsey, JR; Grosfeld, D; Henkle, B; Herberich, B; Hsieh, F; Lee, MR; Li, V; Middleton, S; Pettus, L; Plant, MH; Reed, AB; Reichelt, A; Rzasa, RM; Sham, K; Sherman, L; Syed, R; Tasker, AS; Thaman, M; Wong, LM; Wurz, RP; Xu, S; Zhang, D, 2008
)
0.35
" Simulations showed good agreement with plasma levels measured after oral dosing in dogs."( Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic Analysis.
Crison, J; Fung, NK; Good, DJ; Haddadin, R; Hartley, R; Hussain, M; Koo, O; Mathias, N; Nikfar, F; Timmins, P; Tirucherai, G, 2015
)
0.42
" The effects of dosing of granular activated carbon (GAC) and polyaluminum chloride (PACl) on the treatment performance and membrane fouling of anaerobic ceramic membrane bioreactor were investigated for treating phenol- and quinoline-containing wastewater."( Membrane fouling and performance of anaerobic ceramic membrane bioreactor treating phenol- and quinoline-containing wastewater: granular activated carbon vs polyaluminum chloride.
Hu, Z; Ma, C; Pang, C; Wang, S; Wang, W, 2019
)
0.92
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
mancude organic heterobicyclic parent
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
azaarene
ortho-fused heteroareneAn ortho-fused compound in which at least one of the rings contains at least one heteroatom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
chaperonin-containing TCP-1 beta subunit homologHomo sapiens (human)Potency100.00003.981127.764939.8107AID504842
GLI family zinc finger 3Homo sapiens (human)Potency43.45320.000714.592883.7951AID1259392
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency37.65050.011212.4002100.0000AID1030
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency42.23590.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency5.76310.001530.607315,848.9004AID1224841; AID1224842
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency58.43860.057821.109761.2679AID1159528
heat shock protein beta-1Homo sapiens (human)Potency60.16990.042027.378961.6448AID743210; AID743228
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
Alpha-synucleinHomo sapiens (human)Potency3.98110.56239.398525.1189AID652106
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (101)

Processvia Protein(s)Taxonomy
superoxide anion generationNeutrophil cytosol factor 1Homo sapiens (human)
protein targeting to membraneNeutrophil cytosol factor 1Homo sapiens (human)
superoxide metabolic processNeutrophil cytosol factor 1Homo sapiens (human)
cellular defense responseNeutrophil cytosol factor 1Homo sapiens (human)
cellular response to reactive oxygen speciesNeutrophil cytosol factor 1Homo sapiens (human)
superoxide anion generationNeutrophil cytosol factor 1Homo sapiens (human)
innate immune responseNeutrophil cytosol factor 1Homo sapiens (human)
respiratory burstNeutrophil cytosol factor 1Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityNeutrophil cytosol factor 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionNeutrophil cytosol factor 1Homo sapiens (human)
positive regulation of JNK cascadeNeutrophil cytosol factor 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNeutrophil cytosol factor 1Homo sapiens (human)
regulation of respiratory burst involved in inflammatory responseNeutrophil cytosol factor 1Homo sapiens (human)
cellular response to cadmium ionNeutrophil cytosol factor 1Homo sapiens (human)
cellular response to glucose stimulusNeutrophil cytosol factor 1Homo sapiens (human)
cellular response to testosterone stimulusNeutrophil cytosol factor 1Homo sapiens (human)
positive regulation of p38MAPK cascadeNeutrophil cytosol factor 1Homo sapiens (human)
reactive oxygen species biosynthetic processNeutrophil cytosol factor 1Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
nicotinamide metabolic processNicotinamide N-methyltransferaseHomo sapiens (human)
response to xenobiotic stimulusNicotinamide N-methyltransferaseHomo sapiens (human)
response to organonitrogen compoundNicotinamide N-methyltransferaseHomo sapiens (human)
animal organ regenerationNicotinamide N-methyltransferaseHomo sapiens (human)
methylationNicotinamide N-methyltransferaseHomo sapiens (human)
NAD biosynthesis via nicotinamide riboside salvage pathwayNicotinamide N-methyltransferaseHomo sapiens (human)
positive regulation of gluconeogenesisNicotinamide N-methyltransferaseHomo sapiens (human)
positive regulation of protein deacetylationNicotinamide N-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
protein bindingNeutrophil cytosol factor 1Homo sapiens (human)
electron transfer activityNeutrophil cytosol factor 1Homo sapiens (human)
superoxide-generating NAD(P)H oxidase activityNeutrophil cytosol factor 1Homo sapiens (human)
SH3 domain bindingNeutrophil cytosol factor 1Homo sapiens (human)
phosphatidylinositol bindingNeutrophil cytosol factor 1Homo sapiens (human)
phosphatidylinositol-3,4-bisphosphate bindingNeutrophil cytosol factor 1Homo sapiens (human)
superoxide-generating NADPH oxidase activator activityNeutrophil cytosol factor 1Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
nicotinamide N-methyltransferase activityNicotinamide N-methyltransferaseHomo sapiens (human)
pyridine N-methyltransferase activityNicotinamide N-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
cytosolNeutrophil cytosol factor 1Homo sapiens (human)
plasma membraneNeutrophil cytosol factor 1Homo sapiens (human)
cytoplasmic side of plasma membraneNeutrophil cytosol factor 1Homo sapiens (human)
membraneNeutrophil cytosol factor 1Homo sapiens (human)
dendriteNeutrophil cytosol factor 1Homo sapiens (human)
phagolysosomeNeutrophil cytosol factor 1Homo sapiens (human)
NADPH oxidase complexNeutrophil cytosol factor 1Homo sapiens (human)
neuronal cell bodyNeutrophil cytosol factor 1Homo sapiens (human)
cytoplasmNeutrophil cytosol factor 1Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
cytosolNicotinamide N-methyltransferaseHomo sapiens (human)
cytosolNicotinamide N-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (78)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1599237Toxicity in BALB/c mouse infected with Leishmania donovani MHOM/IN/80/Dd8 promastigotes assessed as reduction in body weight at 25 mg/kg, po administered once daily for 5 days measured up to 7 days post dose2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Synthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral Leishmaniasis.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1599225Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 promastigotes infected in BALB/c mouse assessed as reduction in parasite load in liver at 50 mg/kg, ip administered once daily for 5 days measured 7 days post dose by giemsa staining-base2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Synthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral Leishmaniasis.
AID1599238Toxicity in BALB/c mouse infected with Leishmania donovani MHOM/IN/80/Dd8 promastigotes assessed as death at 50 mg/kg, ip administered once daily for 5 days measured up to 7 days post dose2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Synthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral Leishmaniasis.
AID343680Hexadecane-water distribution coefficient, log D at pH 7.4 by shake-flask technique2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID1219902Activity of guinea pig cytosolic aldehyde oxidase2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID1599233Toxicity in BALB/c mouse infected with Leishmania donovani MHOM/IN/80/Dd8 promastigotes assessed as effect on health at 12.5 to 200 mg/kg, ip administered once daily for 5 days measured up to 7 days post dose2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Synthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral Leishmaniasis.
AID1525699Substrate activity at aldehyde oxidase in rat liver cytosol assessed as enzyme-mediated drug uptake at 1 uM2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery.
AID61001The maximal DA release induced by perfusion with 10 mM MPP+ (15 min) 1 day after perfusion with the test compound with basal striatal DA (%of basal x10E-3)1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
In vivo intracerebral microdialysis studies in rats of MPP+ analogues and related charged species.
AID637444Antioxidant activity against toxin solution-induced lipid peroxidation in Sprague-Dawley rat brain homogenates assessed as free MDA levels per mg of tissue at 1 by TBARS assay (Rvb = 0.93 +/- 0.09 nmol)2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID1599202Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 amastigotes harboring luciferase reporter gene infected in mouse J774 cells at 25 uM after 48 hrs by Steady-Glo luminescence assay relative to control2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Synthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral Leishmaniasis.
AID125789Inhibitory effect on Bufuralol 1'-hydroxylation by human liver microsomes (Ki = apparent inhibition constant)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1599239Toxicity in BALB/c mouse infected with Leishmania donovani MHOM/IN/80/Dd8 promastigotes assessed as effect on health at 50 mg/kg, ip administered once daily for 5 days measured up to 7 days post dose2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Synthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral Leishmaniasis.
AID1599235Toxicity in BALB/c mouse infected with Leishmania donovani MHOM/IN/80/Dd8 promastigotes assessed as death at 25 mg/kg, po administered once daily for 5 days measured up to 7 days post dose2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Synthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral Leishmaniasis.
AID158544In vitro antiplasmodial activity against Plasmodium falciparum D102000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Structure-function relationships in aminoquinolines: effect of amino and chloro groups on quinoline-hematin complex formation, inhibition of beta-hematin formation, and antiplasmodial activity.
AID29421Partition coefficient (logP) (HPLC)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID637441Antioxidant activity against toxin solution-induced lipid peroxidation in Sprague-Dawley rat brain homogenates assessed as free MDA levels per mg of tissue at 0.001 by TBARS assay (Rvb = 0.93 +/- 0.09 nmol)2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1599234Toxicity in BALB/c mouse infected with Leishmania donovani MHOM/IN/80/Dd8 promastigotes assessed as reduction in body weight at 12.5 to 200 mg/kg, ip administered once daily for 5 days measured up to 7 days post dose2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Synthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral Leishmaniasis.
AID1525700Substrate activity at aldehyde oxidase in guinea pig liver cytosol assessed as enzyme-mediated drug uptake at 1 uM2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery.
AID1525698Substrate activity at aldehyde oxidase in human liver cytosol assessed as enzyme-mediated drug uptake at 1 uM2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery.
AID1182519Radioprotective activity against gamma-irradiated human MOLT4 cells preincubated for 1 hr at 100 to 400 uM before gamma-irradiation measured after 18 hrs by erythrosine B dye-exclusion test2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Design and synthesis of 8-hydroxyquinoline-based radioprotective agents.
AID1145386Partition coefficient, log P of the compound by shake-flask technique1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Direct measurement of octanol-water partition coefficients by high-pressure liquid chromatography.
AID668289Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay2012European journal of medicinal chemistry, Aug, Volume: 54Discovery of a new antileishmanial hit in 8-nitroquinoline series.
AID1586851Displacement of DC271 from CRABP2 (unknown origin) at 200 to 1600 nM by fluorescence assay2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
Novel Fluorescence Competition Assay for Retinoic Acid Binding Proteins.
AID219087Association constant with ferriprotoporphyrin IX.2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Structure-function relationships in aminoquinolines: effect of amino and chloro groups on quinoline-hematin complex formation, inhibition of beta-hematin formation, and antiplasmodial activity.
AID226297Inhibition of Beta-hematin (hemozoin) formation; No inhibition.2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Structure-function relationships in aminoquinolines: effect of amino and chloro groups on quinoline-hematin complex formation, inhibition of beta-hematin formation, and antiplasmodial activity.
AID1599224Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 promastigotes infected in BALB/c mouse assessed as reduction in parasite load in spleen at 50 mg/kg, ip administered once daily for 5 days measured 7 days post dose by giemsa staining-bas2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Synthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral Leishmaniasis.
AID74835Inhibitory activity against vesicular glutamate transport (GVT) in synaptic vesicles isolated from rat forebrain1999Bioorganic & medicinal chemistry letters, Sep-06, Volume: 9, Issue:17
Quinoline-2,4-dicarboxylic acids: synthesis and evaluation as inhibitors of the glutamate vesicular transport system.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID637436Antioxidant activity assessed as AAPH-induced peroxyl radical scavenging activity at 1 mM by ORAC assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID25367Compound was evaluated for the pKa value in water at 20 degrees Centigrade1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
In vitro antimalarial activity of chalcones and their derivatives.
AID1145387Partition coefficient, log P of the compound by HPLC analysis1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Direct measurement of octanol-water partition coefficients by high-pressure liquid chromatography.
AID1599199Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 promastigotes harboring luciferase reporter gene at 50 uM after 48 hrs by Steady-Glo luminescence assay relative to control2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Synthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral Leishmaniasis.
AID637443Antioxidant activity against toxin solution-induced lipid peroxidation in Sprague-Dawley rat brain homogenates assessed as free MDA levels per mg of tissue at 0.1 by TBARS assay (Rvb = 0.93 +/- 0.09 nmol)2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID637439Antioxidant activity assessed as trolox equivalents ratio of ferric ion reducing activity using fe3+-TPTZ at 0.1 mM by FRAP assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID238164Displacement of PRP-1 peptide from mouse Tec kinase SH3 domain by fluorescence polarization; No binding2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Identification and specificity studies of small-molecule ligands for SH3 protein domains.
AID29176Dissociation constent of compound at 20 degree C1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
2,4-Diamino-5-benzylpyrimidines and analogues as antibacterial agents. 11. Quinolylmethyl analogues with basic substituents conveying specificity.
AID168703Inhibition of Rana pipiens muscle activity.1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID1599200Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 promastigotes harboring luciferase reporter gene at 25 uM after 48 hrs by Steady-Glo luminescence assay relative to control2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Synthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral Leishmaniasis.
AID1599236Toxicity in BALB/c mouse infected with Leishmania donovani MHOM/IN/80/Dd8 promastigotes assessed as effect on health at 25 mg/kg, po administered once daily for 5 days measured up to 7 days post dose2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Synthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral Leishmaniasis.
AID1599232Toxicity in BALB/c mouse infected with Leishmania donovani MHOM/IN/80/Dd8 promastigotes assessed as death at 12.5 to 200 mg/kg, ip administered once daily for 5 days measured up to 7 days post dose2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Synthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral Leishmaniasis.
AID637438Antioxidant activity assessed as trolox equivalents ratio of ferric ion reducing activity using fe3+-TPTZ at 0.01 mM by FRAP assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID637442Antioxidant activity against toxin solution-induced lipid peroxidation in Sprague-Dawley rat brain homogenates assessed as free MDA levels per mg of tissue at 0.01 by TBARS assay (Rvb = 0.93 +/- 0.09 nmol)2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID27580Partition coefficient (logP)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID1599201Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 amastigotes harboring luciferase reporter gene infected in mouse J774 cells at 50 uM after 48 hrs by Steady-Glo luminescence assay relative to control2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Synthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral Leishmaniasis.
AID343398Octanol-water distribution coefficient, log D at pH 7.4 by shake-flask technique2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID1364303Antiparasitic activity against Toxoplasma gondii after 4 days by chlorophenol red-beta-D-galactosidase based assay2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Recent developments in drug discovery against the protozoal parasites Cryptosporidium and Toxoplasma.
AID1582677Binding affinity to immobilized recombinant human His-tagged p47phox SH3A-B domain (151 to 285 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as maximal response by SPR assay relative to quinolin-2-amine2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.
AID668283Antileishmanial activity against Leishmania donovani MHOM/IN/00/DEVI promastigotes after 72 hrs by MTT assay2012European journal of medicinal chemistry, Aug, Volume: 54Discovery of a new antileishmanial hit in 8-nitroquinoline series.
AID637440Antioxidant activity assessed as ferric ion reducing activity using fe3+-TPTZ at 1 mM by FRAP assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID637437Antioxidant activity assessed as trolox equivalents ratio of ferric ion reducing activity using fe3+-TPTZ at 0.001 mM by FRAP assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID1582668Covalent inhibition of recombinant human His-tagged p47phox SH3A-B domain (151 to 285 residues) expressed in Escherichia coli BL21 (DE3) cells interaction with Cy5-p22phox149-162 incubated for 10 mins by fluorescence polarization competition assay2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.
AID1599240Toxicity in BALB/c mouse infected with Leishmania donovani MHOM/IN/80/Dd8 promastigotes assessed as reduction in body weight at 50 mg/kg, ip administered once daily for 5 days measured up to 7 days post dose2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Synthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral Leishmaniasis.
AID1219903Ratio of Km to Vmax for guinea pig cytosolic aldehyde oxidase2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID668288Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay2012European journal of medicinal chemistry, Aug, Volume: 54Discovery of a new antileishmanial hit in 8-nitroquinoline series.
AID61002The maximum dopamine release induced by perfusion with the test compound with basal striatal DA (%of basal x10E-3)1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
In vivo intracerebral microdialysis studies in rats of MPP+ analogues and related charged species.
AID19427HPLC capacity factor (k)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID342464Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The many roles for fluorine in medicinal chemistry.
AID644414Lipophilicity, log D of the compound in octanol-water at pH 7.4 by reverse-phase HPLC analysis2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).
AID637434Antioxidant activity assessed as trolox equivalents ratio of AAPH-induced peroxyl radical scavenging activity at 0.001 mM by ORAC assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antioxidant properties of 4-quinolones and structurally related flavones.
AID1802032NNMT Enzymatic Activity Assay from Article 10.1021/acs.biochem.6b00733: \\A Rapid and Efficient Assay for the Characterization of Substrates and Inhibitors of Nicotinamide N-Methyltransferase.\\2016Biochemistry, 09-20, Volume: 55, Issue:37
A Rapid and Efficient Assay for the Characterization of Substrates and Inhibitors of Nicotinamide N-Methyltransferase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,217)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990289 (23.75)18.7374
1990's45 (3.70)18.2507
2000's196 (16.11)29.6817
2010's550 (45.19)24.3611
2020's137 (11.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 81.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index81.95 (24.57)
Research Supply Index7.13 (2.92)
Research Growth Index5.10 (4.65)
Search Engine Demand Index146.64 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (81.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.08%)5.53%
Reviews48 (3.84%)6.00%
Case Studies4 (0.32%)4.05%
Observational0 (0.00%)0.25%
Other1,198 (95.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]